Pulmonology

Orphan drug designation granted for treatment of pulmonary infections in patients with cystic fibrosis

The U.S. Food and Drug Administration has granted orphan drug designation for inhalation delivery of pravibismane (BisEDT antimicrobial suspension) for treatment (management) of pulmonary infections in patients with cystic fibrosis. “We are pleased to have been granted orphan drug designation for our pravibismane inhalation program,” said Mr. Karim Lalji, Chairman and...